Farhad Vahid | Breast Cancer | Editorial Board Member

Dr. Farhad Vahid | Breast Cancer | Editorial Board Member

Assistance Professor | Luxembourg Institute of Health | Luxembourg

Dr. Farhad Vahid is a prominent researcher at the Luxembourg Institute of Health, Strassen, specializing in nutritional epidemiology, diet-related cardiometabolic health, and public health interventions. His research focuses on understanding the impact of dietary patterns, inflammatory indices, antioxidants, and nutrient intake on chronic diseases, including cardiovascular risk, obesity, breast cancer, and reproductive health. Dr. Vahid has contributed to advancing population-based and clinical research through large cohort studies, randomized clinical trials, and systematic reviews, providing evidence for the development of diet quality indices and population health guidelines. His work emphasizes the intersection of nutrition, chronic disease prevention, and healthy aging, with translational implications for both individual and public health outcomes. Over his career, he has demonstrated strong collaborative engagement, working with multidisciplinary teams across international institutions to address global health challenges through diet and lifestyle interventions. Dr. Vahid’s publications, including studies on dietary carotenoids, the dietary inflammatory index, cardiovascular risk factors, and healthy aging, have informed both scientific understanding and practical public health strategies. His research not only contributes to academic knowledge but also has significant societal impact by guiding nutritional recommendations and interventions aimed at reducing chronic disease burden and promoting population health. Dr. Vahid’s academic influence and research productivity are reflected in his metrics 1,529 citations, 100 documents, and an h-index of 22.

Featured Publications

Vahid, F., Zand, H., Nosrat–Mirshekarlou, E., Najafi, R., & Hekmatdoost, A. (2015). The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: A review. Gene, 562(1), 8–15. Cited by 237.

Vahid, F., Shivappa, N., Hekmatdoost, A., Hebert, J. R., Davoodi, S. H., & Sadeghi, M. (2017). Association between maternal dietary inflammatory index (DII) and abortion in Iranian women and validation of DII with serum concentration of inflammatory factors: Case-control study. Applied Physiology, Nutrition, and Metabolism, 42(5), 511–516. Cited by 110.

Ashkar, F., Rezaei, S., Salahshoornezhad, S., Vahid, F., Gholamalizadeh, M., & [others]. (2020). The role of medicinal herbs in treatment of insulin resistance in patients with polycystic ovary syndrome: A literature review. Biomolecular Concepts, 11(1), 57–75. Cited by 96.

Vahid, F., Shivappa, N., Faghfoori, Z., Khodabakhshi, A., Zayeri, F., & Hebert, J. R. (2018). Validation of a dietary inflammatory index (DII) and association with risk of gastric cancer: A case-control study. Asian Pacific Journal of Cancer Prevention: APJCP, 19(6), 1471. Cited by 92.

Vahid, F., Shivappa, N., Karamati, M., Naeini, A. J., Hebert, J. R., & Davoodi, S. H. (2017). Association between dietary inflammatory index (DII) and risk of prediabetes: A case-control study. Applied Physiology, Nutrition, and Metabolism, 42(4), 399–404. Cited by 85.

Gerardo Rosati | Breast Cancer | Best Researcher Award

Dr. Gerardo Rosati | Breast Cancer | Best Researcher Award

Azienda Ospedaliera San Carlo di Potenza | Italy

Dr. Gerardo Rosati is a distinguished Italian medical oncologist whose career reflects over three decades of sustained clinical practice, research leadership, and commitment to advancing evidence-based cancer care. Laureato con lode all’Università “Federico II” di Napoli e successivamente specializzato in Oncologia presso la Seconda Università di Napoli, ha sviluppato precocemente un interesse scientifico per i markers tumorali e per l’innovazione terapeutica nei tumori solidi. La sua formazione è stata arricchita da numerose borse di studio FIRC, ESO e Fondazione Lina Belli, che gli hanno consentito di partecipare a corsi avanzati internazionali su colon-retto, neuro-oncologia, recidive ginecologiche, terapia antalgica e strategie emergenti in oncologia medica. Dal 1998 opera stabilmente presso l’U.O. di Oncologia Medica dell’Azienda Ospedaliera “S. Carlo” di Potenza, dove ha assunto ruoli via via più qualificati fino alla responsabilità del coordinamento dell’attività di ricerca clinica. La sua attività come sperimentatore in oltre cento studi clinici di fase I–III e in numerosi progetti osservazionali riguarda chemioterapie innovative, farmaci biologici, anti-EGFR, anti-angiogenici, immunoterapia, tossicità correlate ai trattamenti e biomarcatori predittivi. Ha inoltre svolto un’intensa attività di revisione scientifica per riviste internazionali e per enti accademici e sanitari nazionali, contribuendo al miglioramento della qualità metodologica della ricerca oncologica. Membro attivo di AIOM, ESMO ed ESO College, promuove l’integrazione tra clinica, ricerca e formazione, con un impatto significativo sui percorsi assistenziali nei tumori gastrointestinali e in altre neoplasie solide. His academic influence is reflected in 2,813 citations, 123 documents, and an h-index of 27, underscoring his meaningful contributions to contemporary clinical oncology.

Profiles: Scopus | ORCID

Featured Publications

1. Rosati, G., De Stefano, A., Restivo, A., Fanotto, V., Cicero, G., Colombo, A., Dell’Aquila, E., Parisi, A., Ortolani, S., Lutrino, S. E., Carlomagno, C., Dapoto, F., Reggiardo, G., Tonetto, F., Ravo, V., Aprile, G., Bilancia, D., Avallone, A., Romano, C., Argiolas, V., & Giovinazzo, G. (2026). Short-Course Radiotherapy for Older Patients with Locally Advanced Rectal Cancer and Unfit for Chemotherapy: The SOFT Study. Radiotherapy and Oncology.

2. Rosati, G., Piccirillo, M. C., Nasti, G., De Stefano, A., Carlomagno, C., Romano, C., Cassata, A., Silvestro, L., Nappi, A., Perrone, F., Budillon, A., & Avallone, A. (2025). A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study. Drugs & Aging, 1–10.

3. Avallone, A., Giuliani, F., De Stefano, A., Santabarbara, G., Nasti, G., Montesarchio, V., Rosati, G., Cassata, A., Leo, S., Romano, C., Tamburini, E., Silvestro, L., Lotesoriere, C., Nappi, A., Santini, D., Petrillo, A., Colombo, A., Febbraro, A., Leone, A., Mannavola, F., & Laterza, M. M. (2024). Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. Journal of Clinical Oncology, 43(7), 829–839.

4. Montrone, M., Rosati, G., Longo, V., Catino, A., Massafra, R., Nardone, A., Pesola, F., Montagna, E. S., Marech, I., & Pizzutilo, P. (2023). Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. Journal of Clinical Medicine, 12(5), 1833.

5. Rosati, G., Montrone, M., Pacilio, C., Colombo, A., Cicero, G., Paragliola, F., Vaia, A., Annunziata, L., & Bilancia, D. (2022). An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer. Journal of Clinical Medicine, 11(23), 7108.

Hongyu li | Breast Cancer | Best Researcher Award

Hongyu li | Breast Cancer | Best Researcher Award

Xinjiang medical university | China

AUTHOR PROFILE

SCOPUS

🎓EARLY ACADEMIC PURSUITS 

Assoc. Prof. Dr. Hongyu Li embarked on her academic journey at Xinjiang Medical University, where she earned her Doctor of Medicine degree and subsequently completed a Ph.D. in 2021. Her formative years were marked by rigorous academic training and an early interest in the oncology of breast diseases, which laid the foundation for her future specialization in breast cancer metastasis research.

👩‍🏢PROFESSIONAL ENDEAVORS 

Currently serving as an Associate Professor, Associate Chief Physician, and Doctor of Medicine at the Department of Breast Internal Medicine, Xinjiang Medical University Affiliated Tumor Hospital, Dr. Li brings over a decade of clinical expertise to the field. Her clinical focus is on the early detection, diagnosis, and management of breast cancer. She has been honored with prestigious awards including the “Tianchi Talent” Youth Doctor Award (2022), the Outstanding Postdoctoral Special Funding (2023), and was selected for the “789 Talent” Training Program (2024), cementing her reputation as a High-Level Talent and Outstanding Young Physician.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BREAST CANCER 

Dr. Li’s scientific inquiry is anchored in understanding the molecular mechanisms of breast cancer metastasis, with a specific focus on breast cancer brain metastasis (BCBM)—a critical and poorly understood manifestation associated with poor prognosis. Her translational research bridges clinical challenges and bench-side investigations, aiming to identify novel biomarkers and potential therapeutic targets for BCBM.

She adopts an integrative approach that translates clinical observations into mechanistic questions, enhancing the effectiveness of future treatments and diagnostic strategies for late-stage breast cancer.

📚IMPACT AND INFLUENCE 

Dr. Li’s work is contributing to shaping the clinical paradigms in breast cancer care within the Xinjiang region and beyond. Her research is improving understanding of metastatic processes, especially in underrepresented ethnic populations. She is also involved in institutional collaborations and has served in editorial capacities, reinforcing her influence in both academic and clinical oncology spheres.

💪LEGACY AND FUTURE CONTRIBUTIONS 

Looking forward, Dr. Li aims to establish a dedicated translational research unit focused on metastatic breast cancer, particularly BCBM. She is committed to mentoring young researchers and expanding interdisciplinary collaborations that bridge molecular oncology with precision medicine. Her ultimate goal is to redefine treatment algorithms and enhance survival outcomes for patients with advanced-stage breast cancer.

🌍CONCLUSION 

Assoc. Prof. Dr. Hongyu Li stands as a beacon of translational oncology, seamlessly integrating clinical care with cutting-edge research. Her relentless pursuit of knowledge, commitment to public health, and strategic focus on a critically unmet need in oncology make her a deserving nominee for the Best Researcher Award.

 

📊🔬NOTABLE PUBLICATION:

Title: GRB2 promotes brain metastasis in HER2-positive breast cancer by regulating the Ras/MAPK pathway

Authors: Hongyu Li, Yalin Zhang, Xiao Han, Bingyu Li, Dan Liu, Gang Sun

Journal: Scientific Reports (Nature Publishing Group)

Year: 2025